Management of asthma in Benin: the challenge of loss to follow-up

Adé, G.; Gninafon, M.; Tawo, Leon; Aït-Khaled, N; Da, Enarson; Cy, Chiang

doi:10.5588/pha.12.0080

Cited by 17 publications

(14 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Before the asthma pilot project, only a small minority of asthma patients were prescribed with ICS in Benin [ 12 ]. The CAL asthma pilot project began with national adaption of international asthma guidelines, followed by training of clinicians for guideline implementation.…”

Section: Discussionmentioning

confidence: 99%

“…Most asthma patients have had to pay out of pocket for health services. Before the asthma pilot project, the majority of asthma patients were being treated exclusively on an emergency basis when they presented with an acute attack of asthma and that only a small minority of asthma patients were prescribed with ICS in Benin [ 12 ].…”

Section: Methodsmentioning

confidence: 99%

“…A project introducing a comprehensive approach to lung health (CAL), funded by the World Bank and implemented through collaboration between the International Union Against Tuberculosis and Lung Disease (The Union) and partners in Benin, China and Sudan, included as one of its aims to reduce the burden of lung disease through management of patients with persistent asthma [ 12 , 13 ]. In Benin, it was implemented in 2008 at two public health facilities (Centre national hospitalier de pneumophtisiologie (CNHP) in Cotonou and one tuberculosis unit located in Porto-Novo) and three missionary health facilities.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of a revolving drug fund for essential asthma medicines in Benin

Agodokpessi¹,

Aït-Khaled

Gninafon³

et al. 2015

J of Pharm Policy and Pract

View full text Add to dashboard Cite

ObjectivesBenin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013.MethodsWe reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013.ResultsThe total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013.ConclusionThe Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of a revolving drug fund for essential asthma medicines in Benin

Agodokpessi¹,

Aït-Khaled

Gninafon³

et al. 2015

J of Pharm Policy and Pract

View full text Add to dashboard Cite

show abstract

“…Another study from Sudan, focusing on severe cases, revealed a loss to follow-up of 56%, 9 and another from Benin reported 36% loss to follow-up. 10 These findings suggest the need for more effective tracing strategies for asthma patients on follow-up.…”

Section: Discussionmentioning

confidence: 99%

How well are asthma treatment cards filled out in public health centres in Gazeera State, Sudan?

Kodouda¹,

Zachariah

Khogali

et al. 2014

public health action

View full text Add to dashboard Cite

“…GAN Phase I is a development from ISAAC ( particularly Phases One [17][18][19][20][21] and Three [22][23][24]), and The Union [11,12,14,25]. GAN Phase I has extended its surveillance to include adults, for whom there are limited global data, and to assess asthma management, which is commonly suboptimal in settings with limited access to quality-assured essential asthma medicines.…”

Section: Introductionmentioning

confidence: 99%

The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors

Ellwood

Asher

Ne³

et al. 2016

Eur Respir J

152

136

View full text Add to dashboard Cite

The Global Asthma Network (GAN), established in 2012, followed the International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries where severity was also high, and identified several environmental factors that required further investigation.GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management and use of asthma essential medicines. The subjects will be the same age groups as ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further evidence will be obtained to understand asthma, management practices and risk factors, leading to further recognition that asthma is an important non-communicable disease and to reduce its global burden.

show abstract

Management of asthma in Benin: the challenge of loss to follow-up

Cited by 17 publications

References 13 publications

Assessment of a revolving drug fund for essential asthma medicines in Benin

Assessment of a revolving drug fund for essential asthma medicines in Benin

How well are asthma treatment cards filled out in public health centres in Gazeera State, Sudan?

The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors

Contact Info

Product

Resources

About